Clinical Chemistry, Malmö
951 – 960 of 1293
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening
(
- Contribution to journal › Article
-
Mark
Factor V Leiden in pregnancies complicated by placental abruption
(
- Contribution to journal › Article
-
Mark
Probing plasma clearance of the thrombin-antithrombin complex with a monoclonal antibody against the putative serpin-enzyme complex receptor-binding site.
(
- Contribution to journal › Article
-
Mark
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
(
- Contribution to journal › Article
-
Mark
Stabilyte (TM) tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor
(
- Contribution to journal › Letter
-
Mark
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
(
- Contribution to journal › Article
-
Mark
Diagnosing protein S deficiency: analytical considerations.
(
- Contribution to journal › Article
-
Mark
Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women.
(
- Contribution to journal › Article
-
Mark
Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.
(
- Contribution to journal › Article
-
Mark
Activated protein C resistance (FVLeiden) and thrombosis: factor V mutations causing hypercoagulable states
(
- Contribution to journal › Scientific review